Uridine triacetate
- Generic Name
- Uridine triacetate
- Brand Names
- Vistogard, Xuriden
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N2O9
- CAS Number
- 4105-38-8
- Unique Ingredient Identifier
- 2WP61F175M
- Background
Uridine triacetate, formerly known as vistonuridine, is an orally active prodrug of the naturally occurring nucleoside uridine. It is used for the treatment of hereditary orotic aciduria (Xuriden), or for the emergency treatment of fluorouracil or capecitabine overdose or toxicity (Vistogard). It is provided in the prodrug form as uridine triacetate as this ...
- Indication
Marketed as the product Xuriden (FDA), uridine triacetate is indicated for the treatment of hereditary orotic aciduria.
...
- Associated Conditions
- Orotic aciduria, Capecitabine overdose, Fluorouracil overdose
- Associated Therapies
- -
Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT02110147
- Locations
- 🇺🇸
Children's Hospital of Michigan - Specialty Center Detroit, Detroit, Michigan, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
- Conditions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Wellstat Therapeutics
- Registration Number
- NCT01432301
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
- Conditions
- Interventions
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 65
- Registration Number
- NCT00004233
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 250
- Registration Number
- NCT00024427
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Cancer Center at Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸Fox Chase - Temple Cancer Center, Philadelphia, Pennsylvania, United States
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2002-09-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT00044785
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.